IL308733A - Fc variant with increased affinity for Fc receptors and improved thermal stability - Google Patents

Fc variant with increased affinity for Fc receptors and improved thermal stability

Info

Publication number
IL308733A
IL308733A IL308733A IL30873323A IL308733A IL 308733 A IL308733 A IL 308733A IL 308733 A IL308733 A IL 308733A IL 30873323 A IL30873323 A IL 30873323A IL 308733 A IL308733 A IL 308733A
Authority
IL
Israel
Prior art keywords
receptors
variant
thermal stability
improved thermal
enhanced affinity
Prior art date
Application number
IL308733A
Other languages
English (en)
Hebrew (he)
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of IL308733A publication Critical patent/IL308733A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IL308733A 2021-05-27 2022-05-27 Fc variant with increased affinity for Fc receptors and improved thermal stability IL308733A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163193665P 2021-05-27 2021-05-27
EP21315127 2021-07-15
PCT/IB2022/055019 WO2022249146A1 (en) 2021-05-27 2022-05-27 Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY

Publications (1)

Publication Number Publication Date
IL308733A true IL308733A (en) 2024-01-01

Family

ID=82358573

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308733A IL308733A (en) 2021-05-27 2022-05-27 Fc variant with increased affinity for Fc receptors and improved thermal stability

Country Status (12)

Country Link
US (2) US12297273B2 (https=)
EP (1) EP4347640A1 (https=)
JP (1) JP2024522092A (https=)
KR (1) KR20240015093A (https=)
AU (1) AU2022282666A1 (https=)
BR (1) BR112023022584A2 (https=)
CA (1) CA3216005A1 (https=)
CO (1) CO2023016432A2 (https=)
IL (1) IL308733A (https=)
MX (1) MX2023014100A (https=)
TW (1) TW202306584A (https=)
WO (1) WO2022249146A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12286475B2 (en) 2023-07-31 2025-04-29 Sanofi Anti-GPRC5D antibodies and compositions

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
BR9606706A (pt) 1995-10-16 1999-04-06 Unilever Nv Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
CA2410551A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US7312181B2 (en) 2005-04-08 2007-12-25 Cropsolution, Inc. Acylated thiosemicarbazides as herbicides
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
JP5898082B2 (ja) * 2009-10-07 2016-04-06 マクロジェニクス，インコーポレーテッド フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法
TWI743461B (zh) 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
EP2825557B1 (en) * 2012-03-16 2017-06-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Soluble engineered monomeric fc
US10011660B2 (en) 2012-04-30 2018-07-03 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
ES2876009T3 (es) 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Polipéptido heterodimerizado
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
CN120988137A (zh) 2015-01-23 2025-11-21 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
EA201891753A1 (ru) * 2016-02-03 2019-01-31 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки
CA3020633A1 (en) 2016-04-13 2017-10-19 Sanofi Trispecific and/or trivalent binding proteins
AR108963A1 (es) 2016-04-13 2018-10-17 Merial Inc Dispositivo de inyección con mecanismo de accionamiento para administrar múltiples formulaciones líquidas, tales como vacunas
CN108218998A (zh) * 2017-12-31 2018-06-29 武汉班科生物技术股份有限公司 一种突变型人源IgG的Fc片段及其制备方法与应用
IL276286B2 (en) 2018-01-26 2025-07-01 Genzyme Corp FC variants with improved binding to FCRN and extended half-life
WO2019185164A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules
JP7792330B2 (ja) * 2019-09-03 2025-12-25 アムジエン・インコーポレーテツド Ｉｌ－２２の経口、直腸内、又は他の消化管関連の組成物及びそれを使用する方法

Also Published As

Publication number Publication date
AU2022282666A1 (en) 2024-01-18
CA3216005A1 (en) 2022-12-01
BR112023022584A2 (pt) 2024-01-09
CO2023016432A2 (es) 2023-12-11
US20230077531A1 (en) 2023-03-16
MX2023014100A (es) 2023-12-11
US20250376526A1 (en) 2025-12-11
KR20240015093A (ko) 2024-02-02
TW202306584A (zh) 2023-02-16
US12297273B2 (en) 2025-05-13
WO2022249146A1 (en) 2022-12-01
JP2024522092A (ja) 2024-06-11
EP4347640A1 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
MX368665B (es) Variantes de fc.
LTC2356151I2 (lt) Didelio afiniškumo žmogaus antikūnai prieš žmogaus IK-4 receptorius
SMT201600387B (it) MUTANTI DI Fc DI ANTICORPI CON ABLAZIONE DI FUNZIONI EFFETTRICI
PH12015501097A1 (en) Heterodimeric immunoglobulins
UA115563C2 (uk) Ізольоване джерело тепла
IL235355A0 (en) Enhanced affinity t cell receptors and methods for making the same
EP2950375A4 (en) ULTRA-FINE FIBER CARBON FOR NON-ACRYLIC ELECTROLYTE SECONDARY BATTERY, ULTRA-FINE FIBER-CARBON FIBER, COMPOSITE BODY, AND ACTIVE MATERIAL LAYER OF AN ELECTRODE
EP2201517A4 (en) CONTENT DISTRIBUTION IN THE OPEN MARKET
GB2515970A (en) Cable holder
IL308733A (en) Fc variant with increased affinity for Fc receptors and improved thermal stability
EP2909733A4 (en) TRACKABLE DIVISION OF ONLINE VIDEO CONTENT
DK3585182T3 (da) Anvendelse af en fodersammensætning til reducering af methanudslip fra drøvtyggere og/eller til forbedring af drøvtyggeres ydeevne
MX2016000352A (es) Anclaje de roca deformable.
AU2013377729B2 (en) Fibrous composite frame
FR3010701B1 (fr) Agencement d'un reservoir entre un capot de nacelle et une turbomachine
EP2222611A4 (en) STRUCTURAL MATERIALS WITH NEARLY NO CARBON EMISSION
BRPI1011257A2 (pt) "luva de proteção apta a ser instalada em torno de uma porção longitudinal de conduto flexível destinado ao transporte de hidrocarbonetos."
HRP20181386T1 (hr) Hibridni rukav sa staklenim ili keramičkim vlaknima i metalnim vlaknima
EP4424325A4 (en) PEPTIDE WITH AN AFFINITY FOR THE HUMAN TRANSFERRIN RECEPTOR
EP2818315A4 (en) SEALING ELEMENT FROM A VACUUM INSULATING MATERIAL WITH EXCEPTIONAL HITCH AND FIRE RESISTANCE
EP2390048A4 (en) WELDING STRUCTURE WITH EXCELLENT RESISTANCE TO SPROUTING TROUBLE SHOOTING
HK40109227A (en) Fc variant with enhanced affinity to fc receptors and improved thermal stability
CO6970581A2 (es) Movilidad y recuperación de hidrocarburos mediante combustión in situ con la adición de amoníaco
CN203248923U (zh) 一种管道保温结构
EP2685138A4 (en) SEAL AND GASKET STRUCTURE